Anebulo Pharmaceuticals, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

289

Shareholding (Mar 2025)

FII

0.43%

Held by 2 FIIs

DII

98.56%

Held by 3 DIIs

Promoter

0.00%

How big is Anebulo Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Anebulo Pharmaceuticals, Inc. has a market capitalization of 60.39 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -7.69 million over the last four quarters. As of Jun 24, the company's shareholder's funds were 3.81 million, and total assets were 4.07 million.

What does Anebulo Pharmaceuticals, Inc. do?

22-Jun-2025

Anebulo Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $60.39 million. The company has no dividends, a negative debt equity ratio, and a return on equity of -57.12%.

Is Anebulo Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Anebulo Pharmaceuticals, Inc. shows a mildly bullish technical trend with mixed signals from indicators, having outperformed the S&P 500 over the past week but underperformed over the past month.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 90 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.99

Return on Equity

-57.12%

Price to Book

6.71

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-4.47%

6 Months

117.59%

1 Year

51.61%

2 Years

-0.84%

3 Years

-11.32%

4 Years

-65.54%

5 Years

0.0%

Anebulo Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Anebulo Pharmaceuticals, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Anebulo Pharmaceuticals, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The weekly RSI is bearish, and there is no signal on the monthly RSI. Bollinger Bands indicate a bullish stance on the weekly and mildly bullish on the monthly. Moving averages are bullish on the daily timeframe. The KST shows a bullish trend weekly and mildly bullish monthly. Dow Theory indicates no trend weekly but mildly bullish monthly. The OBV is mildly bullish weekly and mildly bearish monthly. In terms of performance, the stock has outperformed the S&P 500 over the past week with a return of 22.89% compared to 1.05%, but it has underperformed over the past month with a return of -4.26% versus 2.33%. Year-to-date, the stock is up 47.02% compared to the S&P 500's 12.22%. Overall, the current technical stance is m...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-215.15%

EBIT to Interest (avg)

-6.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

55.78%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.30

EV to EBIT

-3.78

EV to EBITDA

-3.78

EV to Capital Employed

31.09

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-823.30%

ROE (Latest)

-57.12%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (1.01%)

Foreign Institutions

Held by 2 Foreign Institutions (0.43%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2025 is 0.00% vs 39.29% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-1.70",
          "chgp": "-11.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.70",
          "val2": "-1.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 29.91% vs -72.06% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-8.30",
          "val2": "-11.80",
          "chgp": "29.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.20",
          "val2": "-11.70",
          "chgp": "29.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Mar'25

Mar'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.90

-1.70

-11.76%

Interest

0.20

0.10

100.00%

Exceptional Items

0.00

Consolidate Net Profit

-1.70

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Consolidated Net Profit

YoY Growth in quarter ended Mar 2025 is 0.00% vs 39.29% in Mar 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Jun'24

Jun'24

Jun'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-8.30

-11.80

29.66%

Interest

0.20

0.00

Exceptional Items

0.00

Consolidate Net Profit

-8.20

-11.70

29.91%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Jun 2024 is 0.00% vs 0.00% in Jun 2023

Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 29.91% vs -72.06% in Jun 2023

All Annual Results

Company CV

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Anebulo Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Anebulo Pharmaceuticals, Inc.?

Watch in Real-Time

What does Anebulo Pharmaceuticals, Inc. do?

Is Anebulo Pharmaceuticals, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Anebulo Pharmaceuticals, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Mar'25 - YoY

Annual Results Snapshot (Consolidated) - Jun'24

About Anebulo Pharmaceuticals, Inc.

Company Coordinates